Sorry, we couldn't find any content.
Browse our FDA ADVOCACY work:
FOR IMMEDIATE RELEASE Contact: Evita Almassi, email@example.com
Testimony Delivered at the Meeting of the FDA Bone, Reproductive and Urologic Drugs Advisory Committee
[FDA-2019-N-4203] Bone, Reproductive, and Urological Products Advisory Committee Notice of Meeting, Establishment of Public Docket, Requests for Comments Submitted electronically To Whom It May Concern: The National Women’s Health Network (NWHN) is a nonprofit advocacy organization that works to improve...
The National Women’s Health Network (The NWHN) believes that more needs to be done to protect people against unnecessary harm caused by silicone gel-filled breast implants. Implants have been on the market for more than 30 years, and during that...
Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.
The NWHN and 42 organizations sent a letter today to the House Energy and Commerce Committee applauding their work on a bipartisan discussion draft to address cosmetics safety.
Opioid dependency is a bodily adaptation that is likely to disproportionately affect women, because they are more likely to develop opioid dependency in a shorter period of time, compared to men.
The public pays for more than half of the FDA's budget each year, which entitles us to have a say in the agency’s operations. Late last year, we gave your predecessor, Scott Gottlieb, a report card on his first year...
The NWHN’s Statement on the FDA Ordering Manufacturers of Surgical Mesh to Stop Selling Devices for Uterine ProlapseBy: Cindy Pearson ,FDA Advocacy, Gynecological Health, Pelvic Organ Prolapse, Surgical Mesh, Transvaginal Mesh Press Releases
FOR IMMEDIATE RELEASE Contact: Evita Almassi, firstname.lastname@example.org or (202) 682-6240